PapersFlow Research Brief
Chemotherapy-related skin toxicity
Research Guide
What is Chemotherapy-related skin toxicity?
Chemotherapy-related skin toxicity refers to dermatological side effects and complications caused by antineoplastic agents, including extravasation, hand-foot syndrome, radiation recall dermatitis, and nail changes.
This field encompasses 37,112 works on skin toxicities from chemotherapy drugs such as taxanes, platinum agents, and pegylated liposomal doxorubicin. Common manifestations include hand-foot syndrome from pegylated liposomal doxorubicin and hypersensitivity reactions from paclitaxel. Management and prevention strategies address these dermatological complications to support ongoing cancer treatment.
Topic Hierarchy
Research Sub-Topics
Hand-Foot Syndrome in Chemotherapy
This sub-topic investigates the pathophysiology, incidence, and risk factors of palmar-plantar erythrodysesthesia induced by agents like capecitabine and doxorubicin. Researchers study preventive measures and symptomatic treatments.
Chemotherapy Extravasation Management
This sub-topic covers protocols for preventing, detecting, and treating inadvertent leakage of vesicant chemotherapeutic agents into tissues. Researchers evaluate antidotes, nursing interventions, and long-term tissue outcomes.
Radiation Recall Dermatitis from Chemotherapy
This sub-topic examines the inflammatory skin reactions in previously irradiated areas triggered by systemic chemotherapy. Researchers explore mechanisms, implicated drugs, and dermatological interventions.
Chemotherapy-Induced Nail Changes
This sub-topic analyzes onychodystrophy, Beau's lines, and pigmentation alterations caused by cytotoxic agents. Researchers assess epidemiology, predisposing factors, and supportive care options.
Pegylated Liposomal Doxorubicin Dermatotoxicity
This sub-topic focuses on skin toxicities specific to pegylated liposomal doxorubicin, including reduced cardiotoxicity trade-offs. Researchers compare formulations and develop mitigation strategies.
Why It Matters
Chemotherapy-related skin toxicity affects patient quality of life and can necessitate dose reductions or treatment interruptions, as seen in paclitaxel administration where 32 of 301 patients experienced definite hypersensitivity reactions including skin involvement (Weiss et al., 1990, "Hypersensitivity reactions from taxol."). Pegylated liposomal doxorubicin reduces cardiotoxicity compared to conventional doxorubicin while maintaining efficacy in metastatic breast cancer, though it is associated with palmar-plantar erythrodysesthesia, a form of hand-foot syndrome (O’Brien et al., 2004, "Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer"). Platinum drugs like cisplatin, carboplatin, and oxaliplatin cause skin side effects among their seven types of toxicities, impacting dermatology in oncology care (Oun et al., 2018, "The side effects of platinum-based chemotherapy drugs: a review for chemists"). These toxicities require targeted interventions to enable safer chemotherapy delivery.
Reading Guide
Where to Start
"Paclitaxel (Taxol)" by Rowinsky and Donehower (1995) provides an accessible entry point as it introduces taxane mechanisms, clinical activity, and associated skin toxicities like hypersensitivity reactions in a broad oncology context.
Key Papers Explained
Rowinsky and Donehower (1995, "Paclitaxel (Taxol)") establishes taxane cytotoxic effects and skin-related hypersensitivities, which Weiss et al. (1990, "Hypersensitivity reactions from taxol.") quantifies in 32 of 301 patients. Gelderblom et al. (2001, "Cremophor EL") explains the solvent's role in these reactions, while O’Brien et al. (2004, "Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer") contrasts this with hand-foot syndrome from liposomal doxorubicin. Oun et al. (2018, "The side effects of platinum-based chemotherapy drugs: a review for chemists") extends to platinum agents' seven side effect types including skin issues.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Current research builds on taxane solvent toxicities and hand-foot syndrome mechanisms, with focus on predictive factors for hypersensitivities and platinum skin effects, though no recent preprints are available.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Paclitaxel (Taxol) | 1995 | New England Journal of... | 1.8K | ✕ |
| 2 | Reduced cardiotoxicity and comparable efficacy in a phase IIIt... | 2004 | Annals of Oncology | 1.7K | ✓ |
| 3 | Cremophor EL | 2001 | European Journal of Ca... | 1.6K | ✕ |
| 4 | The side effects of platinum-based chemotherapy drugs: a revie... | 2018 | Dalton Transactions | 1.6K | ✕ |
| 5 | Incidence, prevalence, and predictors of chemotherapy-induced ... | 2014 | Pain | 1.4K | ✓ |
| 6 | Combination Chemotherapy in the Treatment of Advanced Hodgkin'... | 1970 | Annals of Internal Med... | 1.4K | ✕ |
| 7 | Prevention and Management of Chemotherapy-Induced Peripheral N... | 2014 | Journal of Clinical On... | 1.2K | ✓ |
| 8 | Hypersensitivity reactions from taxol. | 1990 | Journal of Clinical On... | 1.2K | ✕ |
| 9 | Physicochemical hydrodynamics | 1963 | International Journal ... | 1.1K | ✕ |
| 10 | Paclitaxel and its formulations | 2002 | International Journal ... | 1.1K | ✕ |
Frequently Asked Questions
What skin toxicities are associated with paclitaxel?
Paclitaxel induces hypersensitivity reactions, observed in 32 of 301 patients treated, which can include skin manifestations (Weiss et al., 1990, "Hypersensitivity reactions from taxol."). These reactions stem from the Cremophor EL vehicle used in its formulation (Gelderblom et al., 2001, "Cremophor EL"). Management involves premedication to mitigate acute skin responses.
How does pegylated liposomal doxorubicin cause skin toxicity?
Pegylated liposomal doxorubicin is linked to hand-foot syndrome, also known as palmar-plantar erythrodysesthesia, in breast cancer treatment (O’Brien et al., 2004, "Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer"). This formulation alters toxicity profiles compared to conventional doxorubicin. Prevention includes dose adjustments and skin care protocols.
What are the skin side effects of platinum-based chemotherapy?
Platinum drugs cisplatin, carboplatin, and oxaliplatin produce seven types of side effects, including dermatological reactions (Oun et al., 2018, "The side effects of platinum-based chemotherapy drugs: a review for chemists"). These can manifest as rashes or other skin changes. Clinical management focuses on supportive dermatologic care.
What role does Cremophor EL play in chemotherapy skin toxicity?
Cremophor EL, the solvent for paclitaxel, contributes to hypersensitivity reactions with skin involvement (Gelderblom et al., 2001, "Cremophor EL"; Rowinsky and Donehower, 1995, "Paclitaxel (Taxol)"). It triggers acute responses in a subset of patients. Alternative formulations aim to reduce these solvent-related toxicities.
How are chemotherapy-induced skin toxicities managed?
Management strategies include dose modification and supportive care for conditions like hand-foot syndrome and extravasation injuries. Prevention involves patient education and monitoring during taxane or anthracycline therapy (Rowinsky and Donehower, 1995, "Paclitaxel (Taxol)"). Clinical guidelines emphasize early intervention to avoid treatment delays.
Open Research Questions
- ? What are the precise mechanisms by which Cremophor EL induces skin hypersensitivity in paclitaxel-treated patients?
- ? How can hand-foot syndrome incidence from pegylated liposomal doxorubicin be minimized without compromising breast cancer efficacy?
- ? Which predictors identify patients at highest risk for platinum drug-related skin toxicities?
- ? What novel formulations reduce dermatological side effects of taxanes while preserving antitumor activity?
Recent Trends
The field includes 37,112 works with no specified 5-year growth rate; established papers highlight persistent challenges like paclitaxel hypersensitivities (Weiss et al., 1990) and pegylated liposomal doxorubicin hand-foot syndrome (O’Brien et al., 2004), with no new preprints or news in the last 12 months indicating steady rather than accelerating publication activity.
Research Chemotherapy-related skin toxicity with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Chemotherapy-related skin toxicity with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers